Jiang Cao

Jiang Cao

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MRMuhammad Saif Ur Rahman
Muhammad Saif Ur Rahman
JCJiang Cao
Jiang Cao
Worldwide, gastric cancer is one of the most common malignancies with high mortality. Various aspects of the development and progression of gastric cancer continue to be extensively investigated in order to further our understanding and provide more effective means for the prevention, diagnosis, and treatment of the disease. Estrogen receptors (ERs) are steroid hormone receptors that regulate cellular activities in many physiological and pathological processes in different tissues. There are two distinct forms of ERs, namely ERα and ERβ, with several alternative-splicing isoforms for each. They show distinct tissue distribution patterns and exert different biological functions. Dysregulation of ERs has been found to be associated closely with many diseases, including cancer. A number of studies have been conducted to investigate the role of ERs in gastric cancer, the possible mechanisms underlying these roles, and the clinical relevance of deregulated ERs in gastric cancer patients. To date, inconsistent associations of different ERs with gastric cancer have been reported. These inconsistencies may be caused by variations in in vitro cell models and clinical samples, including assay conditions and protocols with regard to different forms of ERs. Given the potential of the deregulated ERs as diagnostic/prognostic markers or therapeutic targets for gastric cancer, it will be important to identify/confirm the association of each ER isoform with gastric cancer, to determine the specific roles and interactions that these individual ER isoforms play under specific conditions in the development and/or progression of gastric cancer, and to elucidate precisely these mechanisms. In this review, we summarize the achievements from early ER studies in gastric cancer to the most up-to-date discoveries, with an effort to provide a comprehensive understanding of the role of ERs roles in gastric cancer and its possible mechanisms. Furthermore, we propose directions for future investigations.

18 July 2017 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
MAMuhammad Umar Ali
Muhammad Umar Ali
MRMuhammad Saif Ur Rahman
Muhammad Saif Ur Rahman
JCJiang Cao
Jiang Cao
PYPing Xi Yuan
Ping Xi Yuan

26 February 2013 in Molecular Oncology
Verified
Journal Article
Closed access
GLGuangliang Li
Guangliang Li
JZJing Zhang
Jing Zhang
KJKetao Jin
Ketao Jin
KHKuifeng He
Kuifeng He
YZYi Zheng
Yi Zheng
LTLisong Teng
Lisong Teng

27 June 2017 in Tumor Biology
Verified
Journal Article
Open access
MAMuhammad Umar Ali
Muhammad Umar Ali
MRMuhammad Saif Ur Rahman
Muhammad Saif Ur Rahman
ZJZhenyu Jia
Zhenyu Jia
JCJiang Cao
Jiang Cao
Recent technological advancements have shown tremendous mechanistic accomplishments in our understanding of the mechanism of messenger RNA translation in eukaryotic cells. Eukaryotic messenger RNA translation is very complex process that includes four phases (initiation, elongation, termination, and ribosome recycling) and diverse mechanisms involving protein and non-protein molecules. Translation regulation is principally achieved during initiation step of translation, which is organized by multiple eukaryotic translation initiation factors. Eukaryotic translation initiation factor proteins help in stabilizing the formation of the functional ribosome around the start codon and provide regulatory mechanisms in translation initiation. Dysregulated messenger RNA translation is a common feature of tumorigenesis. Various oncogenic and tumor suppressive genes affect/are affected by the translation machinery, making the components of the translation apparatus promising therapeutic targets for the novel anticancer drug. This review provides details on the role of eukaryotic translation initiation factors in messenger RNA translation initiation, their contribution to onset and progression of tumor, and how dysregulated eukaryotic translation initiation factors can be used as a target to treat carcinogenesis.

1 September 2010 in Journal of the Chinese Medical Association
Verified
Journal Article
Closed access
LTLisong Teng
Lisong Teng
KJKe-Tao Jin
Ke-Tao Jin
KHKui-Feng He
Kui-Feng He
JZJing Zhang
Jing Zhang
HWHao-Hao Wang
Hao-Hao Wang
JCJiang Cao
Jiang Cao
Angiogenesis is one of the key acquired characteristics or "hallmarks" essential for the growth and development of all solid tumor types. The antiangiogenic agent vascular endothelial growth factor-Trap (VEGF-Trap) (aflibercept), which is a composite decoy receptor based on VEGF receptor-1 and VEGF receptor-2 fused to an Fc segment of immunoglobulin G1 that binds specifically to VEGF, has demonstrated preclinical efficacy in a range of different tumor types. VEGF-Trap exerts its antiangiogenic effects through regression of tumor vasculature, remolding or normalization of surviving vasculature, and inhibition of new tumor vessel growth. Preclinical and clinical studies have reported that VEGF-Trap can be combined effectively with both chemotherapy and radiotherapy. This review examines the main effects of VEGF-Trap on tumor vasculature and on different types of solid tumors, and explores the preclinical and clinical benefits of incorporating VEGF-Trap into anticancer treatment strategies.

1 January 2005 in World Journal of Gastroenterology
Verified
Journal Article
Open access
LZLei Zeng
Lei Zeng
JCJiang Cao
Jiang Cao
XZXing Zhang
Xing Zhang
Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract